Indeed, our studies demonstrate that combined inhibition of MEK and CKD4/6 is synergistic in vitro in a variety of KRAS mutant CRC cell lines and yields tumor regression in vivo in cell line xenografts and PDXs of KRAS mutant CRC. The gene discussed is KRAS; the disease is colorectal carcinoma.